JPRN-UMIN000004726招募中2 期
Preoperative Short term endocrine therapy for hormonal receptor positive breast cancer - Preste trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. During pregnancy or lactation 2. With active other cancer 3. History of drug allergy 4. Significant illness that might influence the tolerability of treatment (interstitual pneumonia or lung fibrosis, myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic heart disease, arryhythmia or vascular disorder) 5. Severe myelosuppression 6. Severe kidney failure or liver failure 7. Active infectious disease 8. Inflammatory or bilateral breast cancer 9. Patients whom doctors judged inadequate to the enrollment of this study by other reasons
研究者
相似试验
进行中（未招募）
1 期
POETIC-A: PreOperative Endocrine Therapy for Individualised Care with Abemaciclibon-metastatic operable invasive ER+ HER2- breast cancer in post-menopausal womenMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003897-24-GBThe Institute of Cancer Research2,500
进行中（未招募）
不适用
Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC)EUCTR2007-003877-21-GBInstitute of Cancer Research
进行中（未招募）
不适用
Preoperative hormone therapy for pre- and postmenopausal women with ER positive breast cancer: A double blind randomized parallel group phase II trial, comparing the effect of 2 weeks of preoperative Estetrol with placebo - Preoperative estetrolbreast cancerEUCTR2006-006542-34-ATPantarhei Bioscience B.V.
进行中（未招募）
3 期
A trial of hormone therapy and abemaciclib for early breast cancerOperable invasive breast cancer which is ER positive and HER2 negative, with high (20%) 5-year risk of relapse with endocrine therapy (ET) alone in postmenopausal womenMalignant neoplasm of breastCancerISRCTN89539429Institute of Cancer Research2,032
招募中
不适用
ocal treatment in addition to endocrine therapy in ER-positive/HER2-negative oligo-metastatic breast cancerKCT0003767Yonsei University Health System, Gangnam Severance Hospital110